tiprankstipranks
Trending News
More News >
NewAmsterdam Pharma Company (NAMS)
NASDAQ:NAMS
US Market
Advertisement

NewAmsterdam Pharma Company (NAMS) Ownership - Who Owns NewAmsterdam Pharma Company?

Compare
227 Followers

NewAmsterdam Pharma Company (NAMS) Ownership Overview

16.40%12.72%2.74%0.92%67.23%
16.40% Insiders
2.74% Other Institutional Investors
0.92% ETFs
67.23% Public Companies and
Individual Investors
The ownership structure of NewAmsterdam Pharma Company (NAMS) stock is a mix of institutional, retail, and individual investors. Approximately 16.37% of the company’s stock is owned by Institutional Investors, 16.40% is owned by Insiders, and 67.23% is owned by Public Companies and Individual Investors.
The ownership structure of NewAmsterdam Pharma Company (NAMS) stock is a mix of institutional, retail, and individual investors. Approximately 15.45% of the company’s stock is owned by Institutional Investors, 16.40% is owned by Insiders, and 0.92% is owned by Public Companies and Individual Investors.

Recent Insider Trading Activity

Date
Name
Activity
Value
Sep 17, 2025
xxxxxxxxxxxxx
$15635
Sep 10, 2025
xxxxxxxxxxxxx
$31487
Sep 10, 2025
xxxxxxxxxxxxx
$3874017
Sep 05, 2025
xxxxxxxxxxxxx
$453452

Recent Hedge Fund Trading Activity

Date
Firm
Activity
Value
Jun 30, 2025
xxxxxxxxxxxxx
$15070689
Jun 30, 2025
xxxxxxxxxxxxx
$27742238
Jun 30, 2025
xxxxxxxxxxxxx
$34358237
Jun 30, 2025
xxxxxxxxxxxxx
$92649908

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
10,656,172Insider9.46%257,026,869
10,138,938Institution9.00%244,551,185
8,396,080Institution7.45%202,513,450
6,978,534Institution6.20%168,322,240
6,828,864Insider6.06%164,712,200
5,115,953Institution4.54%123,396,786
2,156,406Institution1.91%52,012,513
1,897,197Institution1.68%45,760,392
1,531,874Institution1.36%36,948,801
838,905Institution0.74%20,234,389

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
8,396,080Institution7.45%202,513,450
2,156,406Institution1.91%52,012,513
838,905Institution0.74%20,234,389
835,935Institution0.74%20,162,752
777,280Institution0.69%18,747,994
732,621Institution0.65%17,670,819
653,206Institution0.58%15,755,329
651,100Institution0.58%15,704,532
473,949Institution0.42%11,431,650
453,541Institution0.40%10,939,409

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
378,118Institution0.34%9,120,206
135,832Institution0.12%2,962,496
125,760Institution0.11%3,033,331
97,099Institution0.09%2,348,825
64,718Institution0.06%1,565,528
55,044Institution0.05%1,327,661
33,696Institution0.03%815,106
25,936Institution0.02%627,392
22,964Institution0.02%555,499
19,401Institution0.02%469,310

FAQ

Who Owns NewAmsterdam Pharma Company (NAMS)?
According to the latest TipRanks data, approximately 2.74% of the company's stock is held by institutional investors, 16.40% is held by insiders, and 67.23% is held by retail investors.
    What percentage of NewAmsterdam Pharma Company (NAMS) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 2.74% of NewAmsterdam Pharma Company (NAMS) stock is held by institutional investors.
      What percentage of NewAmsterdam Pharma Company (NAMS) stock is held by retail investors?
      According to the latest TipRanks data, approximately 67.23% of NewAmsterdam Pharma Company (NAMS) stock is held by retail investors.
        Who owns the most shares of NewAmsterdam Pharma Company (NAMS)?
        ForGrowth NAP B.V. owns the most shares of NewAmsterdam Pharma Company (NAMS).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis